Maxiflo 125 Synchrobreathe Inhaler contains a combination of Formoterol (6mcg) and Fluticasone Propionate (125mcg), designed for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Formoterol is a long-acting beta2-adrenergic agonist (LABA) that provides bronchodilation by relaxing airway smooth muscle, resulting in improved airflow and symptomatic relief. Fluticasone Propionate is a corticosteroid with potent anti-inflammatory properties that reduce airway inflammation, edema, and hyperresponsiveness. The Synchrobreathe inhaler utilizes breath-actuated technology, ensuring efficient and coordinated delivery of medication during inhalation, thereby enhancing patient compliance and therapeutic efficacy. Maxiflo 125 is indicated for patients requiring both bronchodilation and anti-inflammatory control to prevent exacerbations and improve lung function. It is essential to use this medication regularly as prescribed, even in the absence of symptoms, to maintain optimal asthma or COPD control. Common adverse effects may include oropharyngeal candidiasis, hoarseness, and throat irritation; rinsing the mouth after use is recommended to minimize these effects. Maxiflo 125 should be used with caution in patients with cardiovascular disorders, and abrupt discontinuation should be avoided to prevent exacerbation of respiratory symptoms.